Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Advanced Cancer Therapeutics secures licensing deal
March 2008
SHARING OPTIONS:

LOUISVILLE, Ky.Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, recently announced that it has signed an exclusive license to develop and market 3PO and its related compounds, discovered by scientists at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center).

Brown Cancer Center researchers Dr. Jason Chesney and Dr. John Trent discovered that 3PO inhibits a key enzyme, PFKFB3, which suppresses both sugar metabolism and cell proliferation among cancer cells. Compared to healthy cells, cancer cells consume large amounts of sugar as a source of energy to fuel their growth. In addition, 3PO blocks PFKFB3 from signaling to cancer cells to spread or proliferate. The University of Louisville researchers have shown in the laboratory that 3PO could be a promising anti-cancer therapeutic against cancers such as leukemia and solid tumors.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.